AVACC
LIVE

Serial Number

79330273

Owner

Intravacc B.V.

Attorney

Jeffrey H. Greger

Filing Date

Nov 29, 2021

Add to watchlist:

No watchlists yet
View on USPTO

AVACC Trademark

Serial Number: 79330273 • Registration: 7051122

AVACC is a trademark filed by Intravacc B.V. on November 29, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Intravacc B.V. (4 trademarks)

Antonie van Leeuwenhoeklaan 9

Entity Type: 78

Trademark Details

Filing Date

November 29, 2021

Registration Date

May 16, 2023

Published for Opposition

February 28, 2023

Goods & Services

Apparatus and containers for the administration of vaccines and medicines, namely, cups for dispensing medicine, injection needles for the administration of vaccines and medicines, injection instruments without needles for the administration of vaccines and medicines, nose sprayers for medical purposes, and spray syringes for medical purposes; all the aforementioned products not in relation to pharmaceutical medicines for cancer therapies consisting of and/or comprising antibodies; all the aforementioned products not in relation to pharmaceutical medicines for cancer therapies consisting of and/or comprising antibody drug conjugates

Pharmaceutical products and preparations for prevention, treatment and immune therapy and combinations of prevention, treatment and immune therapy of infectious diseases and allergic diseases, as well as pharmaceutical products and preparations against cancer; vaccines; and medicines for human use for prevention, treatment and immune therapy and combinations of prevention, treatment and immune therapy of infectious diseases, allergic diseases and cancer; bacterial and viral vaccines, synthetic, recombinant, peptide, protein, RNA-, DNA- and therapeutic vaccines; all the aforementioned products not in relation to pharmaceutical medicines for cancer therapies consisting of and/or comprising antibodies; all the aforementioned products not in relation to pharmaceutical medicines for cancer therapies consisting of and/or comprising antibody drug conjugates

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 21, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 21, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 21, 2025 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 12, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 21, 2023 FICS
FINAL DISPOSITION PROCESSED
Aug 21, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 16, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 16, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
May 16, 2023 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 28, 2023 NPUB
PUBLISHED FOR OPPOSITION
Feb 28, 2023 PUBO
NOTIFICATION PROCESSED BY IB
Feb 27, 2023 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 8, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 8, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 8, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 20, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 20, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 20, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 20, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 20, 2023 CNEA
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
Jan 6, 2023 LIME
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 3, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 3, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 3, 2022 TROA
LIMITATION OF GOODS RECEIVED FROM IB
Aug 27, 2022 LIMG
REFUSAL PROCESSED BY IB
Jun 7, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 16, 2022 RFCS
REFUSAL PROCESSED BY MPU
May 16, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 1, 2022 RFCR
NON-FINAL ACTION WRITTEN
Mar 31, 2022 CNRT
ASSIGNED TO EXAMINER
Mar 30, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 11, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 7, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 6, 2022 REPR